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Abstract
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Background—The lipidome is rapidly garnering interest in the field of psychiatry. Recent
studies have implicated lipidomic changes across numerous psychiatric disorders. In particular
there is growing evidence that the concentrations of several classes of lipids are altered in those
diagnosed with MDD. However, for lipidomic abnormalities to be considered potential treatment
targets for MDD (rather than secondary manifestations of the disease), a shared etiology between
lipid concentrations and MDD should be demonstrated.
Methods—In a sample of 567 individuals from 37 extended pedigrees (average size 13.57
people, range = 3–80), we used mass-spectrometry lipidomic measures to evaluate the genetic
overlap between twenty-three biologically distinct lipid classes and a dimensional scale of MDD.
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Results—We found that the lipid class with the largest endophenotype ranking value (ERV, a
standardized parametric measure of pleiotropy) were ether-phosphodatidylcholines
(alkylphosphatidylcholine, PC(O) and alkenylphosphatidylcholine, PC(P) subclasses).
Furthermore, we examined the cluster structure of the twenty-five species within the top-ranked
lipid class, and the relationship of those clusters with MDD. This analysis revealed that species
containing arachidonic acid generally exhibited the greatest degree of genetic overlap with MDD.
Conclusions—Thisstudy is the first to demonstrate a shared genetic etiology between MDD and
ether-phosphatidylcholine species containing arachidonic acid, an omega-6 fatty acid that is a
precursor to inflammatory mediators, such as prostaglandins. The study highlights the potential
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utility of the well-characterized linoleic/arachidonic acid inflammation pathway as a diagnostic
marker and/or treatment target for MDD.
Keywords
Affective Disorders; Unipolar Depression; Genetics

Introduction
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Major Depressive Disorder (MDD) is a common and potentially life-threatening disorder of
mood (1). It affects 16.2% of individuals in the US during their lifetime (2) and as such it
incurs great economic cost ($83.1 billion per annum in the US) (3). This is not to mention
the personal cost where the impact of MDD on wellbeing and functioning is in line with that
seen in arthritis and diabetes mellitus (4). Moreover, functional impairments remain after the
remission of a depressive episode (5). Unsurprisingly, the World Health Organization
(WHO) cites MDD as a leading cause of disability worldwide (6). However, despite decades
of research, the etiology of the illness remains largely unknown.
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Lipidomic alterations have been reported in numerous psychiatric disorders, including
schizophrenia (7), autism (8, 9), and bipolar disorder (10–12). In particular, changes in the
lipidome (the complete lipid profile of an organism) have been most consistently associated
with MDD (13). The first indication of this association came from early trials of statins,
statins are cholesterol-lowering drugs prescribed to individuals with increased lipid levels
(14). During the statin trials, the lipid-lowering benefits of statin therapy (i.e. reduced
cardiovascular disease risk) were offset, in some cases, by an increase in suicidality (15–20).
Though, it should be noted that others have reported beneficial effects of statins on
depressive symptomatology when combined with anti-depressant medications including
SSRIs (21, 22). The obvious overlap between suicidality and MDD led some to propose a
direct link between lipids and MDD. Indeed, subsequent studies have reported differences
between depressed and healthy subjects in the concentrations of fatty acids in both animal
models of depression (23–27) and also in clinical populations of humans (28–31); and also
alterations in lipid classes including phospholipids (e.g., phosphatidylcholines (PCs),
lysophosphatidylcholines (LPCs), lysophosphatidylethanolamine (LPEs),
phosphatidylethanolamines (PEs), sphingolipids, and cholesterol esters (32–35). However,
despite strong evidence linking lipid concentrations and MDD, it is currently unclear
whether the lipidomic alterations observed in MDD are secondary to the manifestation of the
illness or its treatment, or whether lipid concentrations are related to the genetic
predisposition for depression. If the latter supposition were true, lipids could be considered a
promising diagnostic and/or treatment target for MDD.
In the present study, we aimed to provide evidence for a shared etiology between lipidomic
concentrations and MDD, and determine which lipid classes, and which species within those
classes, might be most informative when attempting to isolate potential diagnostic and
treatment targets for MDD. To achieve these aims we completed three steps: (1) we ranked
sum concentrations of twenty-three lipid classes by their genetic overlap with MDD and
isolated those classes with the greatest degree of overlap; (2) we took the top-ranked lipid
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classes and investigated the structure of the species within them using cluster analysis; (3)
we evaluated the degree of genetic overlap between each species cluster and MDD in an
attempt to characterize the relationships between the lipids and MDD at the species level.

Methods
Participants

Author Manuscript

Lipidomic and psychiatric data were available from a total 567 participants from 37 families
(average family size = 13.57, range = 3–80) the sample was 64% female and had a mean age
of 49.47 years (SD = 13.31, range = 27–97). The lipidomic data was collected as part of the
San Antonio Family Study (SAFS), diagnostic data were also available in these same
individuals as part of assessments conducted in overlapping individuals as part of the
Genetics of Brain Structure and Function (GOBS) study. GOBS data collection occurred
between 2006 and 2016. Individuals from the SAFS cohort have actively participated in
research for over 18 years. Participants were randomly selected from the community with
the constraints that they were of Mexican American ancestry, part of a large family, and
lived in the San Antonio, TX, region. All participants provided written informed consent in
compliance with the institutional review board at the University of Texas Health Science
Center of San Antonio (36).
Continuous Index of MDD
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All participants received the Mini-International Neuropsychiatric Interview (MINI) (37), a
semi-structured interview augmented to include items on lifetime diagnostic history.
Masters- and doctorate-level research staff, with established reliability for diagnosing
affective disorders (κ ≥ .85), conducted the interviews. All subjects with possible
psychopathology were discussed in case conferences that included licensed psychologists or
psychiatrists. Lifetime consensus diagnoses were determined based on available medical
records, the MINI interview, and the interviewer’s narrative. Consistent with previous work
(38), all items from the Past Major Depressive Episode (A3a–g) section of the MINI were
entered into a confirmatory factor analysis with a single factor, and maximum-likelihood
estimates of the latent factor scores were used as the dimensional scale of MDD. In our
previous study, we demonstrated that this continuous index conferred multiple advantages
for gene-finding efforts over the conventional dichotomous (present-absent) diagnosis of
MDD (for details, see (38). Using conventional diagnoses, 216 individuals endorsed a major
depressive episode in their lifetime while 115 had experienced two or more episodes
(recurrent MDD).
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Lipid Extraction and Analysis Procedure
The lipid extraction procedure used in this sample has been described in detail elsewhere
(see (39,40). Briefly, the San Antonio Family study is part of an ongoing longitudinal
observational investigation comprising four phases of data collection during a 23-year
period. The plasma samples used for lipidomic analysis in the present study were collected
during the first phase, between the years 1992–1996. The order of the plasma samples was
randomized prior to lipid extraction and analysis. Quality control plasma samples were
included at a ratio of 1:18. Total lipid extraction from a 10 mL aliquot of plasma was
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performed by a single phase chloroform:methanol (2:1) extraction after the addition of 15
μL of internal standard mix containin 16 non-physiological or stable isotope lipid standards
(Supplementary Table 1) (41).
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Lipid analysis was performed by liquid chromatography, electrospray ionisation-tandem
mass spectrometry using an Agilent 1200 liquid chromatography system combined with an
Applied Biosystems API 4000 Q/TRAP mass spectrometer with a turboionspray source
(350°C) and Analyst 1.5 data system (41). Liquid chromatography was performed on a
Zorbax C18, 1.8μm, 50 × 2.1 mm column (Agilent Technologies) using the following
gradient conditions (300μL/min) 0% solvent B to 100% solvent B over 8.0 min, 2.5 min at
100% solvent B, a return to 0% solvent B over 0.5 min then 10.5 min at 0% solvent B prior
to the next injection. Diacylglycerol (DG) and triacylglycerol (TG) species (1μL injection)
were analysed in a separate chromatographic run using an isocratic flow (100μL/min) of
85% solvent B over 6 min. Solvents A and B consisted of tetrahydrofuran:methanol:water in
the ratio (30:20:50) and (75:20:5) respectively, both containing 10 mM ammonium formate.
Columns were heated to 50°C and the auto-sampler regulated to 25°C. All other lipid
species (5μL injection) were separated under gradient conditions.
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Multiple reaction monitoring (MRM) experiments were used to analyses lipid species in the
following classes and subclasses: dihydroceramide (dhCer), ceramide (Cer),
monohexosylceramide (MHC), dihexosylceramide (DHC), trihexosylcermide (THC), GM3
ganglioside (GM3), sphingomyelin (SM), phosphatidylcholine (PC),
alkylphosphatidylcholine (PC(O)), alkenylphosphatidylcholine (plasmalogen, PC(P)),
lysophosphatidylcholine (LPC), lysoalkylphosphatidylcholine (lysoplatelet activating factor,
LPC(O)), phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine
(PS), phosphatidylglycerol (PG), cholesterol ester (CE), free cholesterol (COH),
diacylglycerol (DG) and triaclyglycerol (TG) (41–43). A total of 65 diacylglycerol and
triacylglycerol species and 257 other lipid species were analyzed. The mass spectrometry
conditions are shown in Supplementary Table 1. The listed abbreviations are used to refer to
individual lipid species e.g. LPC 22:6, which defines a lysophosphatidylcholine with a fatty
acid containing 22 carbons and six double bonds. A number of lipids contain two fatty acid
chains, for these the mass spectrometry based measurements reflect the sum of the number
of carbons and the sum of the number of double bonds across both fatty acids, rather than
directly determining the constituent fatty acids. In accordance with this, for these species we
denote the combined length and number of double bonds (e.g. PC 36:4). However, it is of
note that the identity of at least the major fatty acids making up such a species in plasma
may be reasonably inferred. Relative lipid amounts were calculated by relating the peak area
of each species to the peak area of the corresponding stable isotope or non-physiological
internal standard. Total lipid classes were calculated from the sum of the individual lipid
species within each class (39).
Quantitative Genetic Analyses
All genetic analyses were performed in SOLAR (39). SOLAR implements maximumlikelihood variance decomposition to determine the contributions of genetic and
environmental influences to a trait by modeling the covariance among family members as a
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function of expected allele sharing given the pedigree (see (40) for a detailed description of
the variance components methods). The genetic analysis was done at the class levels rather
than at the species level in the first instance. We did this because regulation of the lipid
metabolic pathway occurs at the class level, and within each class regulation occurs at the
level of the fatty acid. Thus by focusing at the class level we hoped to constrain the search
space of the lipidome to a set of species and fatty acids in which we could search for
associations with MDD. The genetic analyses at the class level were conducted in two steps.
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First, univariate polygenic analysis was applied to the individual lipid class sum scores and
the MDD index, as part of this step all traits were converted to ranks and were normalized
using an inverse Gaussian transformation in addition to being residualized for relevant
covariates. Age, age2, sex and their interactions were included as covariates for all traits
while some additional covariates were included only for either the lipid classes or for MDD.
For the lipid classes, some combination of the following metabolic covariates, collected at
the time of blood sampling as part of the SAFS assessment (41), were included: BMI;
antilipid (statin) medication; diabetes status; heart attack; heart surgery; smoking status;
hypertension status. Inclusion of the metabolic covariates was dependent on the significance
of the covariate with the lipid class in question, a liberal threshold of p < 0.10 was applied in
order to increase confidence that important covariates were included. For MDD we included
any alcohol and any substance use disorder.
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Second, bivariate polygenic analysis was applied to each residualized lipid class sum score
combined with the residualized MDD index, wherein the phenotypic covariance between the
lipid score and MDD was decomposed into its genetic and environmental constituents to
determine the extent to which they were influenced by shared genetic effects. Parameter
estimates from the bivariate analyses were used to calculate ERVs for each MDD/lipid class
pairing.
ERV Calculation
The ERV statistic has been described in detail elsewhere (40), but briefly the ERV for the ith
lipid class and MDD is given by:
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Where hi2 denotes the heritability of the ith lipid class, hMDD2 denotes the heritability of the
MDD index, and ρg denotes the genetic correlation between the two traits. The ERV is
simply an effect size bounded between zero and one, it is useful for prioritizing phenotypes
in terms of their shared genetic overlap with a disease of interest. In the present study we
ranked lipid classes by their genetic overlap with MDD. After ranking was performed, we
tested the statistical significance of the genetic correlation between the top-ranked class and
MDD. This approach involved only one null-hypothesis significance test, because we did not
test (and indeed, it was never our intention to test) whether each lipid class was associated
with MDD or not. Instead, we treated this as a parameter-estimation problem, with the ERV
associated with each lipid class as the parameters of interest.
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This set of analysis was done using the lipid species encapsulated by the top-ranked lipid
classes revealed by the above analysis step. This species-level analysis was done to more
finely investigate the genetic overlap of the top-ranked lipid class and MDD. In order to do
this we first applied bivariate polygenic models to all pairs of lipid species and then, using
the genetic correlations estimated from these models, created a genetic correlation matrix of
all species. Next we applied hierarchical cluster analysis, as implemented in R (42) to the
genetic correlation matrix in order to establish clusters of genetically related species. In
more detail, the genetic correlation matrix was converted into a matrix of dissimilarity
scores by subtracting the absolute value of each correlation from 1. Agglomerative
clustering was then applied to this matrix of distance scores. This method of clustering
begins with n clusters where each cluster represents a single item then, at each step, two
clusters are fused together in accordance with the distance values. This analysis was
interpreted using a dendrogram plot where similar traits are on the same limb of the tree and
distinctly different traits are placed on other limbs (43, 44). Scores for the resultant clusters
were derived using principal components analysis where, for each of the clusters all lipid
classes were entered into PCA and the first unrotated principal component scored was
extracted for bivariate polygenic analysis with MDD.
Assignment of fatty acids to phosphatidylcholine species

Author Manuscript

Fatty acid assignments were performed on the quality control pooled plasma sample (n=6
healthy volunteers) used during the lipid analysis for this cohort. The pooled plasma samples
were extracted in the same conditions replacing 10mM ammonium formate with 200μM
lithium acetate in the process. Assignments were made based on the fragmentation patterns
of the lithium adducts as described by Hsu et al (45) using the same chromatography system
as described but with 200μM lithium acetate instead of 10mM ammonium formate.
Scheduled MRMs for the possible fatty acid specific fragments for each phosphatidylcholine
species were used over several injections, resulting in qualitative data of possible
combinations of fatty acids for each of the species. PC(O) species of very low abundance
were not able to be characterized using this approach. Throughout the present manuscript we
follow the naming convention of lipid classes and species outlined by the LIPID MAPS
consortium (46).

Results
Heritability of MDD

Author Manuscript

As has been previously reported the dimensional scale of MDD was deemed to be
significantly heritable (h2 = 0.20, se = 0.06, p = 2.6×10−05) (38).
ERV: Ranking of Lipid Classes by Genetic Overlap with MDD
The endophenotype ranking results are presented in Table 1, which includes a list of the
metabolic covariates that were included in the analysis of each class. The top ranked lipid
class was PC(O) for which ERV = 0.13 (h2 = 0.39, se = 0.06, p = 1.99×10−16). The second
best ranked lipid class using ERV was the PC(P). The genetic correlation between PC(O)
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and PC(P), which are both phosphatidylcholine lipid classes, was high and significant (ρg
= −0.75, p = 1.4×10−07), consequently we elected to sum the two and treat them as a single
trait. This sum score of PC(O) and PC(P) was significantly heritable (h2 = 0.39, se = 0.06, p
= 4.89×10−15), and the genetic correlation between this score and MDD was significant (ρg
= −0.51, p = 0.01). Therefore the lipid classes exhibiting the greatest degree of genetic
overlap with MDD were the ether-phosphatidylcholine classes PC(O) and PC(P), a sum
score of which shared a significant genetic correlation with MDD.
Clustering of PC(O) and PC(P) Lipid Species

Author Manuscript

In order to identify clusters of genetically related species we applied cluster analysis to the
genetic correlation matrix of all ether-phosphatidylcholine species in our top-ranked lipid
classes, PC(O) and PC(P), for MDD. Figure 1 shows the results of the hierarchical cluster
analysis applied to the genetic correlation matrix of all lipid species within the PC(O) and
PC(P) classes. This analysis revealed three primary clusters, one of which is primarily
characterized by those PC(O) and PC(P) species with a relatively lower number of carbon
atoms and double bonds, shown in purple, Cluster 1. Cluster 2, shown in orange,
encapsulates those species with a relatively higher number of carbon atoms and double
bonds. Finally, PC(O-40:7), PC(O-36:0), PC(O) 34:0 and PC(O) 36:1 were deemed to be
outliers, belonging to neither cluster, given their position on a separate branch of the
dendrogram.
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Genetic Overlap Between Clusters 1 and 2 and MDD—Both Clusters 1 and 2 were
shown to be significantly heritable (Cluster 1: h2 = 0.3684, se = 0.06, p = 4.68×10−15;
Cluster 2: h2 = 0.3965, se = 0.06, p =2.16×10−15). In order to determine which species might
be driving the relationship between MDD and the PC(O) and PC(P) lipid classes we applied
bivariate polygenic analysis. This analysis revealed that only Cluster 2 (ρg = −0.4852, p =
0.01) shared significant genetic overlap with MDD, while the overlap with Cluster 1 was not
significant (ρg = −0.3015, p = 0.1035).
Fatty Acid Assignment of Phosphatidylcholine Species in Cluster 2
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Given that Cluster 2 exhibited a significant genetic overlap with MDD we performed fatty
acid assignments for all ether-phosphatidylcholine species in the cluster. In general,
phosphatidylcholine species consist of 3 different classes; diacyl, alkyl and alkenyl, with
ether-lipids consisting of the latter two. Our initial experiments only determined the total
chain length of the phospholipid (i.e. the sum of carbons and double bonds) as is represented
in Figure 1. The subsequent reanalysis of a pooled plasma sample allowed us to determine
the acyl/alkyl and alkenyl chains and their relative abundance. The majority of the species
observed in Cluster 2 contained either a 20:4 (eicosatetraenoic acid; ETA), a 22:5
(docosapentaenoic acid; DHA) or a 20:5 (eicosapentaenoic acid; EPA) as their sn2 side
chain with as 16:0, 18:0 or 18:1 alkyl/alkenyl chain in the sn1 position (Table 2). It is well
established that in humans ETA (20:4) exists mainly as the omega-6 fatty acid (or,
arachidonic acid) while EPA (20:5) is an omega-3 fatty acid. DHA (22:5) however exists as
both forms, with the majority existing as an omega-3 (47). This means that Cluster 2
represents alkyl- and alkenyl phosphatidylcholine species containing omega 6 and omega 3
fatty acids in the sn2 position. While arachidonic acid is represented by only three of the
Eur Psychiatry. Author manuscript; available in PMC 2018 June 01.

Knowles et al.

Page 8

Author Manuscript

eight species in the cluster, in terms of lipid concentration these species represent
approximately 75% of the total lipids within this cluster. Therefore, Cluster 2 is mostly
characterized by those ether-phosphatidylcholine species containing arachidonic acid.

Discussion
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The aims of the present study were to provide evidence for shared genetic overlap between
lipidomic concentrations and MDD, and to determine which lipid classes, and species, in
particular, might be most informative when attempting to isolate potential biomarkers for
MDD. Numerous studies have highlighted an association between MDD and the lipidome
(32, 34, 35), indeed it has been previously shown that reductions phosphatidylcholine (and
sphingomyelin) concentrations are associated with symptoms of depression (33). However,
previous research has not shown whether the lipid alterations observed in MDD are
secondary to the manifestation of the illness or its treatment, or whether lipid concentrations
are related to the genetic predisposition for depression. Therefore, the present study extends
those findings by showing that: (1) the majority of lipid classes share at least some degree of
genetic overlap with MDD; (2) the classes exhibiting the greatest degree of genetic overlap
with MDD were phospholipid classes PC(O) and PC(P) which are etherphosphatidylcholines; and (3) of those top ranked ether-phosphatidylcholine classes the
species which appeared to be driving the genetic overlap with MDD were mostly those
containing arachidonic acid. These findings are intriguing because they imply that rather
than alterations in phospholipids being secondary to the manifestation of MDD, they might
have a shared etiology with the illness, and as such these lipids, their fatty acids, and their
molecular pathways, might be fruitful candidates when looking to improve diagnostic and
treatment efforts in MDD. Moreover, because the pathways underling arachidonic acid
synthesis and metabolism are well characterized, the present study provides an empirically
testable set of hypotheses for MDD risk, namely the utility of those genes and proteins
encapsulated by arachidonic acid pathways in diagnosing and treating the illness.
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Lipids fulfill a plethora of biological functions (48); they can be stored as forms of energy
(as fats and oils), they play a key role in membrane structure and scaffolding, and they may
actively influence metabolic traffic via roles in cellular regulation, signaling, and
intracellular messaging (49–51). Lipids make up 50% of the weight of the brain, in fact, the
lipid concentration of the brain is second only to adipose tissue (52). Phospholipids can be
broken down into two broad categories, glycerophospholipids (which include
phosphatidylcholines) and sphingolipids, both of which are critical in membrane structure
(49). By virtue of their amphiphilic nature these classes of lipids are able to form a
semipermeable bilayer around a cell and its contents, which consists of a hydrophobic core
of fatty acid tails facing each other and the phospholipid head groups pointing outwards
towards the cell surfaces (49). Thus, these lipid classes are perfectly placed to modulate
signal transduction, molecular recognition processes, and the transportation of ions across
the cell membrane (53). Moreover, the length of the acyl lipid tails) affects bilayer width
which unsurprisingly influences properties such as ion permeability in addition to the
structure and function of membrane proteins (54, 55). Thus ether-phosphatidylcholines, the
class of lipids most strongly associated with MDD in the present study, have an established
role in cell structure and function in the brain.
Eur Psychiatry. Author manuscript; available in PMC 2018 June 01.
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The ether-phosphatidylcholine cluster that showed the greatest degree of genetic overlap
with MDD is characterized by those species that contain omega 6 and omega 3 fatty acids
(arachidonic acid, EPA and DHA), but the majority of fatty acids at the sn 2 position of these
contains an arachidonic acid. In addition, ERV estimates for the individual species in Cluster
2 show that the species sharing the greatest genetic overlap with MDD is one containing
arachidonic acid, species PC(O) 38:4 (Table S2). Arachidonic acid is an omega-6 fatty acid
that is a precursor to a number of eicosanoids (e.g. prostaglandins), which are crucial for the
progression and resolution of inflammatory responses (56). Inflammation has been linked to
the onset of many diseases including, for example, diabetes (57), heart disease (58) and
cancer (59). A number of meta-analyses have implicated the role of inflammation, and
specifically pro-inflammatory cytokines (e.g. IL-6, IL-1β, TNF-α, and CRP), in the etiology
of MDD (60–65). Cytokines feature upstream in the immune response to
phosphatidylcholines and arachidonic acid. Specifically, eicosanoid production may be
triggered when a cell is activated via the release of cytokines, this in turn triggers the release
of a phospholipase (e.g. cytosolic phospholipase A2; cPLA2) at the cell membrane, which
liberates arachidonic acid from the cell membrane phospholipid, rendering the fatty acid
available for eicosanoid production via cyclooxygenase-2 (COX-2) (Figure S1). Thus, the
association of AA containing PC(O) and PC(P) species with MDD may relate to an
underlying chronic inflammation as suggested by the previous literature on cytokines and
depression, and potentially highlights a downstream event underlying the relationship
between inflammation, cytokines and MDD, namely the release of arachidonic acid from the
cell membrane and subsequent eicosanoid synthesis.
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Much attention has been paid to the relationship between dietary intake of omega-3 fatty
acids and depressive symptoms (65–67), and to a lesser extent with a focus specifically on
omega-6 fatty acids (68). For omega-3 fatty acids the results have been largely positive,
although some controversy remains regarding the clinical subgroup for which omega-3 fatty
acids are most beneficial (i.e. sub-clinical versus severe) (69–71). Moreover, two metaanalyses suggest that EPA, as opposed to an alternative fatty acid DHA, which ameliorates
depressive symptoms (72, 73). As highlighted by Kiecolt-Glaser and colleagues in their
recent review (65) this is consistent with the greater anti-inflammatory properties of EPA.
Arachidonic acid is synthesized from dietary intake of linoleic acid (Figure S1) (74). Our
findings suggest that arachidonic acid shares a genetic overlap with MDD, which might
seem contradictory as dietary intake of fatty acids is an environmental factor. However, there
might exist a gene-environment interaction. Or, alterations in the linoleic/arachidonic acid
pathway might disrupt the downstream metabolism of arachidonic acid. Such alterations
might be revealed by a focussed search of genetic variation within those pathways.
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The findings of the present manuscript rely on a peripheral index of lipid levels in the form
of extractions performed on plasma samples. This allows us only to speculate on the ways in
which these findings might be interpreted in the brain. Phosphorous-31 magnetic resonance
spectroscopic (31P MRS) imaging is a method that allows non-invasive measurement of
biological compounds (e.g. phospholipids) in vivo. Alterations in peripheral lipids, including
in phosphatidylcholines, have been noted in psychiatric disorders other than MDD,
including in schizophrenia and bipolar disorder (75, 76). Studies employing MRS techniques
have documented brain-based alterations in membrane phospholipid characteristics in
Eur Psychiatry. Author manuscript; available in PMC 2018 June 01.

Knowles et al.

Page 10

Author Manuscript

schizophrenia (77), bipolar disorder (78), and in MDD (79, 80). Future work might follow
up on the findings in the present manuscript using similar methods.
It is possible that lipidomic abnormalities in relation to affective disorders may be
characterized differently in other ethnic populations. For example, non-Hispanic populations
exhibit altered lipidomic profiles and associated risk for myocardial infarcation relative to
Hispanics (81). Thus it is important that the generalizability of the findings in the present
manuscript should be further tested in future research.
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In summary, the findings presented here highlight ether-phosphatidylcholines, and in
particular those species containing arachidonic acid, as having a sizeable genetic overlap
with MDD. While it has been previously demonstrated that those with MDD exhibit altered
levels of phospholipids, and also arachidonic acid, this is the first study to highlight a shared
genetic etiology between the two. When taken within the context of previous research
demonstrating the role of phospholipids and their fatty acids (and in particular arachidonic
acid) in inflammation, and the wealth of literature linking inflammation and MDD; the
present study, at the very least, highlights the potential utility of ether-phosphatidylcholines
and their biochemical pathways as potentially interesting avenues of research for MDD.
Going further than that, the findings of the present study generate a tentative but testable
hypothesis, which is that the well-characterized linoleic/arachidonic acid inflammation
pathway is a potential diagnostic marker and/or treatment target for MDD.
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Figure 1.

Dendrogram of the cluster analysis of all lipid species contained in the PC(O) and PC(P)
classes. Two main clusters emerged: Cluster 1 (purple), and Cluster 2 (orange), plus two
outliers (green).
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Table 1

Author Manuscript

Ordered Endophenotype Ranking Values (ERVs), Heritability Estimates, Genetic Correlations and Included
Covariates for All Lipid Classes Tested Against MDD
Lipid Class

h2

ρg

ERV

PC(O)

0.39

−0.46

0.13

Smoking

PC(P)

0.42

−0.40

0.12

Diabetes; Smoking; BMI

SM

0.30

−0.45

0.11

BMI

COH

0.38

−0.39

0.11

BMI

Metabolic Covariates Included

Author Manuscript

DHC

0.25

−0.43

0.10

None

MHC

0.49

−0.26

0.09

None

PC

0.54

−0.25

0.08

BMI

PE(P)

0.28

−0.34

0.08

Smoking

LPC(O)

0.38

−0.28

0.08

BMI

THC

0.51

−0.21

0.07

BMI

dhCer

0.49

−0.21

0.07

Diabetes; BMI

Cer

0.30

0.20

0.05

Diabetes

PS

0.38

−0.18

0.05

None

GM

0.35

−0.17

0.05

Diabetes; BMI

PE(O)

0.37

−0.14

0.04

None

LPC

0.34

−0.13

0.04

Diabetes; BMI

Author Manuscript

CE

0.32

−0.12

0.03

Diabetes; BMI

LPE

0.34

−0.09

0.03

Diabetes; BMI

DG

0.31

−0.09

0.02

Diabetes; BMI

TG

0.41

0.05

0.01

Diabetes; BMI

PI

0.40

0.04

0.01

Diabetes; BMI

PE

0.34

−0.03

0.01

Diabetes; BMI

PG

0.40

0.01

0.00

Smoking
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Table 2

Author Manuscript

Fatty acid assignments of the phosphatidylcholine species in cluster 2
Class

Species

Assignment

Fatty Acid

PC(O)

36:4

PC(O)

38:4

PC(O)

38:5

>70% 20:4

PC(P)

38:5

Mix (20:4/22:5/20:5)

arachidonic/docosapentaenoic/eicosapentaenoic acid

PC(P)

40:5

22:6

docosahexaenoic acid

PC(P)

36:5

20:5

eicosapentaenoic acid

PC(O)

35:4

likely 20:41

arachidonic acid

PC(O)

36:5

likely 20:51

eicosapentaenoic acid

20:4
arachidonic acid

1

Author Manuscript

No product ions observed in mass spectra due to low abundance.
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